CARL

144 - CARLSMED, INC. (0001794546) (Subject)

CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society’s 41st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026. "The launch of the Bi-lateral System further expands our proprietary technology platform to enable a direct posterior approach for personalized spine fusion," said Mike Cordonnier, Chairman and CEO of Carlsmed. "The Bi-lateral System is optimized to support pla

4 - CARLSMED, INC. (0001794546) (Issuer)

CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company’s common stock and 89,286 time-based restricted stock units ("RSUs") to Richard Heppenstall, the Company’s newly-hired Chief Financial Officer, as a material inducement to his employment. The Company further announced that on October 1, 2026, it granted stock options to purchase 132,464 shares of the Company’s common stock and 63,735 time-based RSUs to Anthony Jarc, the Company’s ne

4 - CARLSMED, INC. (0001794546) (Issuer)

S-8 - CARLSMED, INC. (0001794546) (Filer)

CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Tony Jarc, Ph.D. has been appointed to the newly-created position of Chief Product and AI Officer, effective immediately. Dr. Jarc will lead the development and commercialization of the Company’s next generation technology platform, surgical UI/UX, and personalized spine surgery procedures. "Tony’s addition comes at a pivotal moment as we transform our technology platform to scale and advance our patient-centric innovation for our highly differentiated personalized surge

3 - CARLSMED, INC. (0001794546) (Issuer)

4 - CARLSMED, INC. (0001794546) (Issuer)

3 - CARLSMED, INC. (0001794546) (Issuer)

8-K - CARLSMED, INC. (0001794546) (Filer)

CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been appointed Chief Financial Officer, effective immediately. Mr. Heppenstall succeeds Leo Greenstein, who has served as CFO since 2023 and will be leaving Carlsmed to pursue other professional interests. "We are excited to welcome Rich to Carlsmed at a pivotal point for the Company," said Mike Cordonnier, Chairman and CEO. "He is a proven leader with the deep Orthopedic and Tech expertise crucial to driving our strategy, and his deep financial

CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. ("DeGen") in the United States District Court for the District of South Carolina Florence Division. The complaint asserts that DeGen is infringing eight of Carlsmed’s patents relating to its implants, methods and systems. Carlsmed is seeking injunctive relief and damages for infringement. "Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and bringing va

4/A - CARLSMED, INC. (0001794546) (Issuer)

4 - CARLSMED, INC. (0001794546) (Issuer)

3 - CARLSMED, INC. (0001794546) (Issuer)

8-K - CARLSMED, INC. (0001794546) (Filer)

CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Jeff Bertolini has been promoted to the role of Chief Operating Officer, effective immediately. Jeff joined Carlsmed in September 2024, most recently serving as the Company’s Senior Vice President, Operational Excellence and previously, Vice President of Advanced Manufacturing Technologies. Prior to joining Carlsmed, Jeff held senior leadership positions in operations and technology at SI-BONE, NuVasive, and US Surgical. "Jeff has made measurable contributions to our op

EFFECT - CARLSMED, INC. (0001794546) (Filer)

10-Q - CARLSMED, INC. (0001794546) (Filer)

8-K - CARLSMED, INC. (0001794546) (Filer)

Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2026. "Our second quarter 2026 results reflect the growing momentum of aprevo® procedures and further progress on our path to profitability," said Mike Cordonnier, Chairman and Chief Executive Officer. "We delivered 57% revenue growth year-over-year, expanded gross mar

CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a favorable reimbursement policy applicable to inpatient aprevo® Lumbar spinal fusion procedures in the Hospital Inpatient Prospective Payment System (IPPS) Final Rule for fiscal year 2027 (FY27). The new MS-DRG assignments and payment rates will go into effect on October 1, 2026. In the FY27 IPPS Final Rule, CMS addressed Carlsmed’s request and reassigned aprevo® Lumbar fusion procedures to three newly cre

CARLSBAD, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions today announced that management will participate in the following investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The Company will host one-on-one meetings on Monday, August 10, 2026.Bank of America SMID Cap Virtual Conference. Fireside chat on Wednesday, August 12, 2026, at 11:00 AM ET. A live webcast will be available to registered participants. Investors interested in participating in virtual one-on-one meetings should contact their Bank of America r

CARLSBAD, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. A live webcast of the conference call will be available in the Events & Presentations section of the company’s investor website at investors.carlsmed.com. Participants may also join via telephone by registering here. A replay will be archived on the company’s website follo